Take Part in an FDA Approved Study for PTSD with the latest Deep TMS TechnologyRead More
This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Ichilov Medical Center, Tel-Aviv, Israel
25 May, 2009
The Purpose of the clinical trial is To evaluate the efficacy of Brainsway® Deep Transcranial Magnetic Stimulation (Deep TMS) with an improved H-coil, which targets deep brain structures, in the treatment of Alzheimer’s patients concomitantly treated with drugs to which they previously failed to respond, or responded only partially.
The Target population of the research study is 45 men and women aged 50-85 with Alzheimer’s disease. The Duration of the clinical trial is 16 weeks for each subject (3 weekly treatment sessions for the first 4 weeks; one weekly session for the latter 4 weeks). A follow-up visit, at which no additional treatment will be administered, will take place 8 weeks after the treatment period.
Study outcome measure is the cognitive response to treatment defined as an improvement of 3 or more points on the ADAS-cog scale at the conclusion of 16 weeks of treatment.
Contact: Adi Shabi +(972) 03-6973698, email@example.com
Principal Investigator: Dr. Ellisa Ash